PDCD1 and neoplasm: Checkpoint blockade antibodies can modulate T-cell function not only within tumors but also during T-cell priming in tumor-draining lymph nodes (TDLNs).11 Understanding the immune characteristics of the CD8+ T cells targeted by anti-PD-1 therapies is critical for optimizing treatment strategies.